Clinical trials: Kidney Disorder
Metastatic Renal Cell Carcinoma
TIL Therapy for Metastatic Renal Cell Carcinoma
Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has achieved impressive clinical results with durable complete responses in patients with metastatic melanoma.
- Trial name
- NCT02926053
- Testing
- Surgical removal of tumor tissue for T cell production, Cyclophosphamide, Fludarabine
- Where
- Denmark
- Volunteers
- 5 people
- Sponsor
- Inge Marie Svane
Chronic Kidney Disease, Iron-deficiency Anemia
A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease
The long-term goal is to assess the fall in kidney function measured by glomerular filtration rate (GFR) when patients with chronic kidney disease (CKD) are exposed to intravenous iron (IVIR).
- Trial name
- NCT00830037
- Testing
- IV Iron, Ferrous Sulfate
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Indiana University
Disorder of Transplanted Kidney
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation
The purpose of this study is to see if treating patients who have high levels of donor specific alloantibodies post-transplant with bortezomib might prevent the development of transplant glomerulopathy and preserve allograft…
- Trial name
- NCT01349595
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mark Stegall
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
Burn Body Region Unspecified, Burn Shock
Enteral Resuscitation Nepal (Pilot Study)
Nepal and the South Asian sub-continent carry some of the highest rates of burn injury globally, with an associated high morbidity and mortality.
- Trial name
- NCT04732624
- Testing
- Oral Rehydration Solution, Lactated Ringer
- Where
- Nepal
- Volunteers
- 30 people
- Sponsor
- University of Washington
Anemia, Renal Diseases
PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients
The purpose of this study is to demonstrate that once every-2-weeks and once every-4-weeks treatment with epoetin alfa, a drug that increases red blood cell production, in patients with anemia associated with chronic kidney…
- Trial name
- NCT00440466
- Testing
- epoetin alfa
- Where
- 66 sites in United States
- Volunteers
- 430 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
- Conditions
- Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy
- Trial name
- RENEW (NCT05162066)
- Testing
- BCX9930
- Where
- 11 sites in France, Italy and 2 more
- Volunteers
- 2 people
- Sponsor
- BioCryst Pharmaceuticals
Pruritis
A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients
Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective.
- Trial name
- CRN11 (NCT01114672)
- Testing
- 50,000 Units Ergocalciferol
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Winthrop University Hospital
Chronic Kidney Disease Requiring Chronic Dialysis
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
This is a Phase 3, randomised, active controlled, multicentre study to investigate the safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients.
- Trial name
- NCT01324128
- Testing
- PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate, PA21-1 (1.25 g tablet containing 250 mg iron)
- Where
- 15 sites in United States, Austria and 13 more
- Volunteers
- 1,059 people
- Sponsor
- Vifor Pharma
VHL Gene Mutation, VHL
MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
The primary objective of this study is to assess the overall response rate (ORR) of von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) tumors in VHL participants treated with MK-3795.
- Conditions
- VHL Gene Mutation, VHL, VHL Syndrome, VHL Gene Inactivation
- Trial name
- NCT03108066
- Testing
- MK-3795
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Heart Failure, Asymptomatic Systolic Dysfunction
Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function
The following are done for screening procedures to determine if patients are eligible for this study: blood count, kidney and liver blood tests. Patients will complete a 6-minute walk test.
- Trial name
- NCT00405639
- Testing
- Nesiritide
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Renal Cell Carcinoma
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
Primary Objective: To determine the progression-free survival (PFS) times for patients with advanced renal cell carcinoma (RCC) treated with decitabine and interferon alfa-2b.
- Trial name
- NCT00561912
- Testing
- Decitabine, Interferon Alfa-2b
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Kidney Diseases
Helping Relationships From Significant Others on Healthy Lifestyle and Quality of Life Among Patients With CKD( CKD Lifestyle)
This clinical trial aims to evaluate the effectiveness of a helping relationships intervention program for patients with chronic kidney disease (CKD).
- Trial name
- CKD lifestyle (NCT02076256)
- Testing
- helping relationships
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Cheng Kung University
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Anemia
A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia
This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous Mircera for the maintenance of hemoglobin levels in hemodialysis patients with chronic renal anemia.
- Trial name
- NCT00661505
- Testing
- methoxy polyethylene glycol-epoetin beta
- Where
- 20 sites in Turkey (Türkiye)
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Dense Deposit Disease, Membranoproliferative Glomerulonephritis
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
This open label, non-blinded, proof of concept efficacy and safety study of eculizumab in patients with biopsy proven DDD or C3 nephropathy.
- Trial name
- NCT01221181
- Testing
- Eculizumab
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Infectious Disease
A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)
This is a 2-part study of the pharmacokinetics (PK) of MK-7655. In Part I, the PK of a single 125 mg dose of MK-7655 given in combination with 250 mg of PRIMAXIN® (imipenem + cilastatin) will be determined in participants with…
- Trial name
- NCT01275170
- Testing
- MK-7655, Imipenem + Cilastatin, Caffeine
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genitourinary Cancer, Kidney Cancer
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
The goal of this clinical research study is to learn more about the safety of giving sunitinib to patients with metastatic kidney cancer for 2 weeks followed by 1 week in which they receive no drug.
- Trial name
- NCT02060370
- Testing
- Sunitinib, Questionnaire
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Renal Cell Carcinoma
Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment
The purpose of this study is to know about the quality of life of patients with metastatic renal cell carcinoma who are being treated with sunitinib, pazopanib or sorafenib, and who suffer from fatigue and hand-foot syndrome…
- Trial name
- TROYA (NCT02789137)
- Where
- 23 sites in Spain
- Volunteers
- 111 people
- Sponsor
- Pfizer
End Stage Renal Disease, Sexual Dysfunction, Physiological
Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients
This study is seeking to identify the most effective strategy to manage pain, sexual dysfunction, and depression in patients receiving chronic hemodialysis therapy.
- Conditions
- End Stage Renal Disease, Sexual Dysfunction, Physiological, Pain, Depression
- Trial name
- SMILE (NCT00692419)
- Testing
- Symptom management nurse intervention, Feedback intervention
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- US Department of Veterans Affairs
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.